期刊
NORDIC JOURNAL OF PSYCHIATRY
卷 71, 期 1, 页码 12-19出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/08039488.2016.1216163
关键词
Biomarkers; diagnostic system; genetics; personalized medicine; psychiatry; RDoC; taxonomy
类别
资金
- Eli Lilly
- Janssen-Ortho
- Shire
- Astra-Zeneca
- Pfizer
- Lundbeck
- Sunovion
- Bristol-Myers Squibb
Background: Personalized medicine is a model in which a patient's unique clinical, genetic, and environmental characteristics are the basis for treatment and prevention.Aim, method, and results: This review aims to describe the current tools, phenomenological features, clinical risk factors, and biomarkers used to provide personalized medicine. Furthermore, this study describes the target areas in which they can be applied including diagnostics, treatment selection and response, assessment of risk of side-effects, and prevention.Discussion and conclusion: Personalized medicine in psychiatry is challenged by the current taxonomy, where the diagnostic categories are broad and great biological heterogeneity exists within each category. There is, thus, a gap between the current advanced research prospects and clinical practice, and the current taxonomy is, thus, a poor basis for biological research. The discussion proposes possible solutions to narrow this gap and to move psychiatric research forward towards personalized medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据